Rachid Bouchikh El Jarroudi

Mr. Rachid Bouchikh El Jarroudi

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2024 in Eye
Verified
Journal Article
Closed access
PDF file
JGJose Galvez-Olortegui
Jose Galvez-Olortegui
RJRachid Bouchikh El Jarroudi
Rachid Bouchikh El Jarroudi
ISIsabel Silva-Ocas
Isabel Silva-Ocas
HPHector Palacios-Herrera
Hector Palacios-Herrera
MCMarta Cubillas-Martin
Marta Cubillas-Martin
TGTomas Galvez-Olortegui
Tomas Galvez-Olortegui

6 January 2026 in Ophthalmologica
Verified
Journal Article
Closed access
RJRachid Bouchikh El Jarroudi
Rachid Bouchikh El Jarroudi
PDPablo Enrique Díaz-Aljaro
Pablo Enrique Díaz-Aljaro
JCJordi Castellví-Manent
Jordi Castellví-Manent
NBNevena Romanic Bubalo
Nevena Romanic Bubalo
RFRubén Dario Fernandez-Torrón
Rubén Dario Fernandez-Torrón
SRSusana Ruiz-Bilbao
Susana Ruiz-Bilbao
Introduction: This article aimed to evaluate the prognostic significance of different optical coherence tomography (OCT) imaging biomarkers in predicting visual outcomes in patients with retinal vein occlusion (RVO). Methods: This was a retrospective study conducted on consecutive patients diagnosed with RVO, who were referred to or treated at a third-level university hospital. The primary endpoints were the mean change in best corrected visual acuity (BCVA) from baseline to the month 6, month 12, and month 18 follow-up visits, and the influence of OCT imaging biomarkers, including ellipsoid zone (EZ) alterations, disorganization of the retinal inner layers (DRILs), hyperreflective foci, neurosensorial detachment, and fibrosis on functional outcomes, defined as a BCVA improvement of ≥5 ETDRS letters. Results: One hundred and sixty-three eyes were included. In the overall study sample, mean (standard error) BCVA increased significantly from 49.6 (1.8) letters at diagnosis to 54.6 (1.8) letters at month 6 (p = 0.0069), 54.3 (1.9) letters at month 12 (p = 0.0071), and 53.6 (1.9) letters at month 18 (p = 0.0313). In multivariate analysis, the presence of EZ alterations at diagnosis (OR: 0.19; p = 0.0008) and their persistence to month 12 (OR: 0.34; p = 0.0043) were associated with a reduced probability of achieving a BCVA improvement of ≥5 ETDRS letters at month 12. By month 18, significant predictors of visual outcomes included EZ alterations at diagnosis (OR: 0.19; p = 0.0008), sustained EZ alterations through 18 months (OR: 0.34; p = 0.0043), and DRIL at month 18 (OR: 0.38; p = 0.0321). Conclusions: The presence of EZ alterations at diagnosis and their persistence at 12 and 18 months, along with DRIL at 18 months, were adverse prognostic markers for BCVA outcomes in patients with RVO.

26 June 2025 in European Journal of Ophthalmology
Verified
Journal Article
Closed access
RJRachid Bouchikh El Jarroudi
Rachid Bouchikh El Jarroudi
KFKolbe Roche Fernández
Kolbe Roche Fernández
ECEster Casas-Gimeno
Ester Casas-Gimeno
HGHugo González-Valdivia
Hugo González-Valdivia
COCarlos Ignacio Ortez-González
Carlos Ignacio Ortez-González
SVSebastian Videla
Sebastian Videla
Background: Blepharospasm is one of the most limiting symptoms in patients with Schwartz-Jampel syndrome and can affect early visual development, causing amblyopia and leading to disability. There is no consensus on the optimal management of blepharospasm in these patients. This systematic review aims to evaluate the current evidence for the appropriate management strategies for blepharospasm in Schwartz-Jampel syndrome. Methods: This was a prospective register of systematic reviews (PROSPERO)-registered (CRD42024569495), Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline-adherent systematic review. Databases searched include Medline (PubMed), Scopus, and Web of Science from any time to February 1st, 2025. All scientific manuscripts published discussing the management of blepharospasm in patients with Schwartz-Jampel syndrome were included. A novel therapeutic algorithm has been developed and proposed. Results: From an initial number of 59 articles, 15 of them were included. No clinical trials nor observational studies were found. All these 15 articles were case series or case reports (quality of evidence: 4 or 5), involving 21 patients. A great heterogeneity in how to manage blepharospasm in Schwartz-Jampel syndrome was gathered. Therapeutic options included oral drugs (sodium channel blockers: carbamazepine, phenytoin, and procainamide), botulinum-toxin-A, and eyelid surgery (orbicularis myectomy). The management algorithm proposal is oral sodium channel blockers as the first option and eyelid surgery as the second option treatment. Botulinum-toxin-A might be considered a therapeutic step prior to surgery. Conclusions: The published evidence regarding management strategies for blepharospasm in Schwartz-Jampel syndrome is scarce and of low quality. Since this nosology is a very rare disease, efforts should be promoted to conduct clinical research and a consensus document for the management of blepharospasm.

28 August 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RJRachid Bouchikh El Jarroudi
Rachid Bouchikh El Jarroudi
ABAlina-Dana Baxant
Alina-Dana Baxant
PSPavel Studeny
Pavel Studeny
KFKolbe Roche Fernández
Kolbe Roche Fernández
ASAdrián Sánchez-Fortún Sánchez
Adrián Sánchez-Fortún Sánchez
PRPau Romera Romero
Pau Romera Romero
Objective: The objective was to provide evidence on the effectiveness (intraocular pressure, IOP) and safety of Deep Sclerectomy with the Esnoper Clip implant with and without the use of mitomycin C (MMC) in uncontrolled primary open-angle glaucoma. Methods: This was a multicentric, retrospective, consecutive case series study undertaken as a collaboration between University Hospital Trias i Pujol, Spain, and University Hospital Kralovske Vinohrady, Czech Republic. The IOP reduction was compared between patients who underwent Deep Sclerectomy with the Esnoper Clip implant, where the antifibrotic agent mitomycin C was used perioperatively (MMC group), and patients who underwent Deep Sclerectomy with Esnoper Clip implants where mitomycin C was not used either peri- or postoperatively (non-MMC group). At the end of the study (12 months after surgery), complete success probability (defined as an IOP <21 mmHg without medication) and qualified success probability (defined as an IOP <21 mmHg with or without medication) were assessed. Safety was based on postoperative complications. A descriptive and exploratory analysis was performed. Results: Between January 2017 and June 2019, a total of 72 consecutive patients (40 women and 32 men; age [median (range)] 70 (39–90)) with uncontrolled primary open-angle glaucoma who underwent Deep Sclerectomy with an Esnoper Clip implant were included. Of these, 78 eyes were included: 44 eyes (38 patients) in the MMC group and 34 eyes (34 patients) in the non-MMC group. At the end of the study (38 and 32 eyes, respectively), the complete success probabilities (95% confidence interval) were 62.2% (51.5–75.2%) and 80.5% (69.5–93.2%), p-value: 0.001; qualified success probability (95% confidence interval): 84.7% (76.6–93.7%) and 85.7% (75.8–97%), p-value: 0.188; and complications (total): 36 and 24, p-value: 0.286. Conclusions: In this case series study, the use of mitomycin C in Deep Sclerectomy with the Esnoper Clip implant for patients with uncontrolled primary open-angle glaucoma does not appear to improve IOP one year after surgery. No safety issues related to mitomycin C were observed. Further study is needed to confirm the effectiveness and to assess long-term safety.

1 April 2025 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
RJRachid Bouchikh El Jarroudi
Rachid Bouchikh El Jarroudi
KFKolbe Roche Fernández
Kolbe Roche Fernández
PRPau Romera Romero
Pau Romera Romero
TCTatiana Croitoru-Croitoru
Tatiana Croitoru-Croitoru
AGAnna Goñi-Guarro
Anna Goñi-Guarro
SVSebastian Videla
Sebastian Videla
Introduction: There are no available data concerning corneal parameters in patients with chronic ocular hypotony. Our purpose is to provide evidence and clinical correlation on the biomechanical corneal changes in chronic hypotonic eyes. Patients and Methods: A single-center, transversal, self-controlled case series study was conducted involving patients with at least one chronic hypotonic eye (defined as an intraocular pressure ≤ 6.5 mmHg measured on three separate occasions for at least three months). The chronic hypotonic eye was the case and the contralateral eye the control (non-hypotonic eye). We collected data from baseline characteristic and intraocular pressure (mmHg). Biomechanical corneal parameters measured by Corvis ST: deformation amplitude ratio (mm), Ambrósio’s relational thickness (μm), stiffness parameter at first applanation (mmHg/mm), Integrated radius (mm− 1), stress-strain index, pachymetry (μm), and in addition macular folds were recorded as well. A descriptive and exploratory analysis was performed. Results: Between November 2021 and July 2023, a total of 16 consecutive patients (7 men, 9 women; age [median (range)]: 72 (62– 84)), diagnosed with chronic ocular hypotony in one eye were included: 16 chronic hypotonic eyes and 16 non-hypotonic eyes. Hypotonic versus non-hypotonic eyes [median (range)]: intraocular pressure: 4 (2– 6) mmHg, 16 (8– 38) mmHg; deformation amplitude ratio: 5.6 (4.3– 6.6) mm, 4.7 (3.9– 5.5) mm, p-value= 0.002; Ambrósio’s relational thickness: 482 (263– 932) μm, 530 (210– 818) μm, p-value: 0.845; stiffness parameter at first applanation: 61.5 (39– 100) mmHg/mm, 113 (68– 130) mmHg/mm, p-value: < 0.001; Integrated radius: 10.9 mm− 1 (6.3– 16.8), 7.9 mm− 1 (6.4– 10.5), p-value: < 0.001; stress-strain index: 0.7 (− 0.2– 4.9), 1.1 (− 2.7– 5.6), p-value: 0.034; pachymetry 509 (456– 617) μm, 512 (436– 775) μm, p-value: 0.637; and macular folds: 7/16, 0/16, p-value: < 0.001. Conclusions: Chronic hypotonic eyes (eyes with a low intraocular pressure) present biomechanical corneal changes with respect to non-hypotonic eyes, mainly in deformation amplitude ratio, stiffness parameter at first applanation, stress-strain index and Ambrósio’s relational thickness parameters. These biomechanical corneal changes could reflect softer, more elastic and deformable scleras, which at its turn can bear higher risk of hypotony maculopathy.

6 January 2025 in Research Square
Verified
Preprint
Open access
PDF file
JGJose Galvez-Olortegui
Jose Galvez-Olortegui
RJRachid Bouchikh El Jarroudi
Rachid Bouchikh El Jarroudi
ISIsabel Silva-Ocas
Isabel Silva-Ocas
SBSusan Bernales-Urbina
Susan Bernales-Urbina
RMRosmery Mollo-Bautista
Rosmery Mollo-Bautista
TGTomas Galvez-Olortegui
Tomas Galvez-Olortegui
Background/Objectives : To assess the methodological quality of Clinical Practice Guidelines(CPG) for the diagnosis and management of open angle glaucoma(OAG). Methods : A systematic review of CPGs for the diagnosis and management of OAG, published between January-2017 and November-2024, was carried out with a search in databases, meta-search engines, CPG development institutions, ophthalmology associations and CPG repositories(PROSPERO:CRD42024510656). 5 authors evaluated them independently, using the Appraisal of Guidelines for Research and Evaluation (AGREE-II) instrument. An individual assessment by domain (AGREE-II), an overall assessment of the guide, and its use with or without modifications was performed. Additionally, a meta-synthesis of the recommendations for the most relevant outcomes was carried out. Results : The lowest mean scores were in applicability and rigour of development(mean 43.2% and 46.1% respectively). The highest score(mean 73.9%) was for domain 4-‘Clarity of presentation’. NICE(92.1%), IETSI(77.5%) and SNSG(75.8%) presented the best score in domain 3-‘Rigour of development’. Only NICE, EGS-5-TGG, SNS, and MaHTAS are recommended, the last two with modifications when evaluating the overall quality of the analyzed CPGs. Most of the CPGs used GRADE approach for making recommendations. In the meta-synthesis, the CPGs show similar recommendations, however, we found variability in indications for selective laser trabeculoplasty(SLT) and minimally invasive glaucoma surgery(MIGS). Conclusions : NICE, IETSI and SNSG CPGs for the diagnosis and management of OAG have a high methodological quality, appraised with AGREE-II. NICE, EGS-5-TGG, IETSI and SNSG have high scores in applicability.